NasdaqGM:HELPPharmaceuticals
Could Helus Pharma’s New CEO Reframe Cybin’s (HELP) Path From Clinical Trials To Commercial Scale?
On August 3, 2026, Helus Pharma appointed Michael Halstead as Chief Executive Officer, bringing 25 years of biopharma experience and a record of leading major drug launches, large-scale integrations and multi billion-dollar M&A transactions.
Halstead’s history of guiding companies from clinical development to full commercial operations may signal a shift in how Helus Pharma approaches growth, partnerships and capital allocation.
We’ll now explore how bringing in a CEO with extensive...